Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...

Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR"), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four ...

Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology -HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals ...

Shareholder/Analyst Call February 5, 2026 3:30 PM ESTCompany ParticipantsRyan Watts - Co-Founder, President, CEO ...

Human newborns arrive remarkably underdeveloped. The reason lies in a deep evolutionary trade-off between big brains, bipedalism and the limits of motherhood.

There are currently no approved disease-modifying therapies for MPS IIIA.

Researchers explored how infants act purposefully by attaching a colorful mobile to their foot and tracking movements with a Vicon 3D motion capture system. The study tested AI's ability to detect ...

Defining the basic elements of personality remains a challenge despite decades of sophisticated research. A new approach drills down into personality’s possible nuances.

Human evolution has long been tied to growing brain size, and new research suggests prenatal hormones may have played a surprising role. By studying the relative lengths of index and ring fingers — a ...